ESID Database Statistics
Last update of this page: April 4, 2018
Total number of patients shown in figures as of June 25, 2014.
Registered in the ESID database by ESID documenting centers (incl. national centers)
These are the final numbers from the old ESID Registry (2004-2014) which was closed for documentation on June 25, 2014.
Statistics from the new ESID Registry will be provided when the verification process for transferred entries has been completed.
Until then advance of the verification process and current figures will be reported through the newsletter.
As of April 4, 2018:
About 70% of the active centres have no datasets left to verify (that have been imported from the old ESID Registry), i.e. the verification process is completed in those documenting centres.
Another 10 % of the active centres have only datasets from less than 10 patients left to verify.
Lithuania is the first country that has completed the verification process of imported data, followed by Croatia, Germany, UK, and Slovenia.
We are also working on a new interactive reporting tool which will allow you to get access to your own centres' data as well as aggregated figures from your country and the overall ESID registry.
This reporting tool will be launched in 2nd quarter 2018.
Documented prevalence of PID in EuropeLiving patients (n) per 100,000 inhibitants (Move mouse over map for more details (Country, number of living patients, prevalence)
Note (1): The map shows the minimal prevalence rates calculated from the number of documented PID patients in the ESID Database.
Note (2): There are patients who are treated outside their country of residence. This means that e.g. a patient is registered by a hospital in Switzerland though he lives in Austria.
Major Immunodeficiency Groups
June 25, 2014
The classification of diseases in the Database was revised in February 2011. This included e.g. adding the category "Defects in innate immunity". The pre-2011 numbers are still based on the old classification.
Compatible web browsers: IE9 and above, Mozilla Firefox, Google Chrome, Opera and Safari for Mac and Windows.